The spotlight falls on the ProPrime II and MeloScript III enzymes, which are engineered to enhance the speed and sensitivity of PCR and qPCR workflows. These tools come with full freedom-to-operate intellectual property protections, allowing manufacturers to integrate them into clinical pipelines with lower regulatory friction. Beyond molecular tools, Fapon is addressing the clinical demand for neurodegenerative diagnostics by offering a comprehensive array of raw materials tailored for blood-based Alzheimer’s biomarker testing, all produced under ISO 13485 standards.
Fapon Debuts AI-Engineered Enzymes and Alzheimer’s Tools at ADLM 2026
In Anaheim, Fapon is positioning its latest diagnostic technologies to capture a larger share of the North American market. At Booth 3161 during the ADLM 2026 conference, the company is unveiling AI-engineered molecular enzymes and a dedicated suite of reagents aimed at accelerating the development of blood-based Alzheimer’s assays.
To support these reagents, the company is running live demonstrations of its Shine i-Series CLIA analyzers, specifically the i1000 and i3000 models. These systems are designed for open-platform compatibility, supporting over 70 in-house assays. This exhibition reinforces Fapon’s "In America, For America" strategy, which centers on maintaining domestic R&D and production infrastructure to ensure supply chain stability for local laboratories. By localizing technical support and manufacturing, the firm aims to provide US-based partners with the consistency required for high-stakes diagnostic development.
Comments (0)
No comments yet. Be the first!